Table 3

Risk factors associated with AAV relapse

	Subgroup	Relapse risk	p Value	OR (95% CI)
Treatment arm	W	32/51 (63%)	<0.0001	5.96 (2.58 to 13.77)
Treatment arm	C	13/59 (22%)	<0.0001	5.96 (2.58 to 13.77)
ANCA specificity at diagnosis	PR3	28/57 (49%)	0.13	1.82 (0.83 to 3.98)
ANCA specificity at diagnosis	MPO	17/49 (35%)	0.13	1.82 (0.83 to 3.98)
ANCA testing at randomisation	Positive	30/58 (51%)	0.017	2.57 (1.16 to 5.68)
ANCA testing at randomisation	Negative	15/51 (29%)	0.017	2.57 (1.16 to 5.68)
Disease	MPA	22/58 (38%)	0.5	0.77 (0.36 to 1.65)
Disease	GPA	23/52 (44%)	0.5	0.77 (0.36 to 1.65)

AAV, ANCA-associated vasculitis; C, continuation subgroup; GPA, granulomatosis with polyangiitis; MPA, microscopic polyangiitis; MPO, myeloperoxidase; PR3, proteinase 3; W, withdrawal subgroup.